DE2617905A1 - 3-dicyclohexylmethyl-piperidin, verfahren zu dessen herstellung und diese verbindung enthaltende arzneimittel - Google Patents
3-dicyclohexylmethyl-piperidin, verfahren zu dessen herstellung und diese verbindung enthaltende arzneimittelInfo
- Publication number
- DE2617905A1 DE2617905A1 DE19762617905 DE2617905A DE2617905A1 DE 2617905 A1 DE2617905 A1 DE 2617905A1 DE 19762617905 DE19762617905 DE 19762617905 DE 2617905 A DE2617905 A DE 2617905A DE 2617905 A1 DE2617905 A1 DE 2617905A1
- Authority
- DE
- Germany
- Prior art keywords
- compound
- acid
- dicyclohexylmethyl
- piperidine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title claims description 20
- 238000000034 method Methods 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title claims description 5
- YYINUTXGJAELSW-UHFFFAOYSA-N 3-(dicyclohexylmethyl)piperidine Chemical compound C1CCCCC1C(C1CNCCC1)C1CCCCC1 YYINUTXGJAELSW-UHFFFAOYSA-N 0.000 title description 6
- 229940126601 medicinal product Drugs 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 239000000812 cholinergic antagonist Substances 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 238000005984 hydrogenation reaction Methods 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- HGVLJGHVYCBNBB-UHFFFAOYSA-N 3-benzhydrylpyridine Chemical compound C1=CC=CC=C1C(C=1C=NC=CC=1)C1=CC=CC=C1 HGVLJGHVYCBNBB-UHFFFAOYSA-N 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000012442 inert solvent Substances 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 239000003071 vasodilator agent Substances 0.000 claims description 2
- 230000002921 anti-spasmodic effect Effects 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000012876 carrier material Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002048 spasmolytic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 230000003170 musculotropic effect Effects 0.000 description 2
- 230000002276 neurotropic effect Effects 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- -1 methanol or Ethanol Chemical compound 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 230000003033 spasmogenic effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7512977A FR2311543A1 (fr) | 1975-04-25 | 1975-04-25 | Dicyclohexylmethyl-3 piperidine utilisable comme medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2617905A1 true DE2617905A1 (de) | 1976-11-04 |
Family
ID=9154491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19762617905 Ceased DE2617905A1 (de) | 1975-04-25 | 1976-04-23 | 3-dicyclohexylmethyl-piperidin, verfahren zu dessen herstellung und diese verbindung enthaltende arzneimittel |
Country Status (4)
| Country | Link |
|---|---|
| BE (1) | BE840410A (enExample) |
| CH (1) | CH601230A5 (enExample) |
| DE (1) | DE2617905A1 (enExample) |
| FR (1) | FR2311543A1 (enExample) |
-
1975
- 1975-04-25 FR FR7512977A patent/FR2311543A1/fr active Granted
-
1976
- 1976-04-06 BE BE1007305A patent/BE840410A/xx not_active IP Right Cessation
- 1976-04-22 CH CH506376A patent/CH601230A5/xx not_active IP Right Cessation
- 1976-04-23 DE DE19762617905 patent/DE2617905A1/de not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CH601230A5 (enExample) | 1978-06-30 |
| BE840410A (fr) | 1976-10-06 |
| FR2311543B1 (enExample) | 1979-06-08 |
| FR2311543A1 (fr) | 1976-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2543184C2 (enExample) | ||
| DE2542881C3 (de) | Razemische oder optisch aktive Benzylalkoholderivate, Verfahren zu ihrer Herstellung und sie enthaltende therapeutische Zubereitung | |
| DE2504045C3 (de) | 16,17 Dihydro-apovincaminsäure-2hydroxypropylester, deren Salze, Verfahren zu ihrer Herstellung und Arzneimittel | |
| DE2635961A1 (de) | Therapeutisch wirksame verbindungen und verfahren zu ihrer herstellung | |
| DE2650845A1 (de) | Neue spiro-(1,3-dioxolan-4,3')- quinuclidine | |
| DE2743166A1 (de) | 2-(3-phenyl-2-amino-propionyloxy)- essigsaeurederivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| DE2632118C3 (de) | Apovincaminolester und Verfahren zu deren Herstellung und Arzneimittel | |
| DE2951247C2 (enExample) | ||
| DE2727144A1 (de) | Arzneimittel auf der grundlage von chinolinderivaten | |
| DE2617905A1 (de) | 3-dicyclohexylmethyl-piperidin, verfahren zu dessen herstellung und diese verbindung enthaltende arzneimittel | |
| DE2824291C2 (de) | Benzylalkohol-Derivate, Verfahren zu deren Herstellung und pharmazeutisches Mittel auf deren Basis | |
| DE2617486A1 (de) | 3,3-dicyclohexyl-propylaminderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| DE2919553A1 (de) | Tetrahydroisochinolinderivat, verfahren zu seiner herstellung und es enthaltende arzneimittel | |
| DE2244737B2 (de) | H-o-ChlorphenyD-2-tert-butylaminoäthanol, Verfahren zu dessen Herstellung und Arzneimittel auf dessen Basis | |
| DE2733056C2 (de) | Vincamenin und seine Säureadditionssalze, solche enthaltende Arzneimittel sowie Verfahren zur Herstellung der genannten Verbindungen | |
| DE2733064A1 (de) | Vincan und seine saeureadditionssalze und quaternaeren vincaniumsalze, solche enthaltende arzneimittel sowie verfahren zur herstellung derselben | |
| DE1668659C3 (de) | Neue Derivate von 2 a, 3 a- Epithioandrostan, Verfahren zu ihrer Herstellung sowie diese enthaltende Mittel | |
| DE2435817B2 (de) | Diaminobenzophenone, ihre Salze, Verfahren zur Herstellung derselben und Arzneimittel | |
| DE2204989C3 (de) | 2-Phenyl-3-(beta-dlmethylaminopropionyl)benzoturan und dessen pharmakologisch verträgliche Säureadditionssalze sowie diese Verbindungen enthaltende Arzneimittel | |
| AT304506B (de) | Verfahren zur Herstellung neuer Anthracenverbindungen | |
| DE1518444C (de) | erythro alpha Phenyl beta amino propanole, Verfahren zu ihrer Herstellung und solche Verbindungen enthaltende Arz neimittel | |
| DE2265580C2 (de) | Heptamethylenimino-alkyl-xanthen-9-carbonsäureester, deren Säureadditionssalze und Verfahren zu deren Herstellung, sowie Arzneimittel, welche diese enthalten | |
| DE2162563B2 (de) | 1 -(3',4'3'-Trimethoxybenzyl)-6-hydroxy-1,2,3,4-tetrahydroisochinolin | |
| AT350526B (de) | Verfahren zur herstellung von neuen 2-amino-1- phenylaethanolen -(1) und von deren salzen | |
| AT379385B (de) | Verfahren zur herstellung neuer indenderivate und ihrer salze |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8131 | Rejection |